Investing.com - テレヘルス企業Hims & Hers Health (NYSE: HIMS )の株価は、製薬大手ノボ・ノルディスク (NYSE: NVO )が減量薬販売に関する同社との提携を終了すると発表した後、32%急落した。

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

Novo Nordisk ended its partnership with Hims & Hers on 23 June 2025, accusing the telehealth firm of selling unsafe, ...

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...

Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ...

Novo Nordisk drops Hims & Hers because it was selling and promoting a cheaper copycat of Wegovy, its weight loss drug.

Hims & Hers stock drops after Wegovy manufacturer ends deal to distribute weight loss drug - Hims & Hers had partnered with ...

The loss of Novo’s involvement significantly dented investor confidence in Hims & Hers, plunging shares in the latter by 35% ...

As such, Novo Nordisk ended its collaboration with Hims & Hers over concerns of illegal mass compounding and deceptive ...

In a statement, Novo Nordisk said that it was terminating the collaboration "due to concerns about their illegal mass ...

Hims & Hers Health’s stock booked record losses Monday after Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ...

The fortune of the San Francisco-based telehealth company’s cofounder and chief executive, Andrew Dudum, crumbled by more ...